Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Karri Stark
Biomarkers and Bone Imaging Dynamics Associated With Clinical Outcomes of Oral Cabozantinib Therapy in Metastatic Castrate Resistant Prostate Cancer
Clinical Cancer Research
Cancer Research
Oncology
Protein Expression of DNA Damage Repair Proteins Dictates Response to Topoisomerase and PARP Inhibitors in Triple-Negative Breast Cancer
PLoS ONE
Multidisciplinary
Related publications
Management of Docetaxel Failures in Metastatic Castrate-Resistant Prostate Cancer
Urologic Clinics of North America
Urology
Current Perspectives on Bone Metastases in Castrate-Resistant Prostate Cancer
Cancer and Metastasis Reviews
Cancer Research
Oncology
Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer With 177 Lu-Psma-617
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Evidence for the Efficacy of Enzalutamide in Postchemotherapy Metastatic Castrate-Resistant Prostate Cancer
Therapeutic Advances in Urology
Urology
Heterogeneous Ensembles for Predicting Survival of Metastatic, Castrate-Resistant Prostate Cancer Patients
F1000Research
Genetics
Molecular Biology
Pharmacology
Biochemistry
Microbiology
Immunology
Medicine
Toxicology
Pharmaceutics
Molecular Drivers of Metastatic Castrate-Resistant Prostate Cancer: New Roads to Resistance
Cancer Biology and Therapy
Cancer Research
Oncology
Molecular Medicine
Pharmacology
Patient Reported Outcomes in Metastatic Castration-Resistant Prostate Cancer
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Prognostic Value of 18f-Fluorocholine PET Parameters in Metastatic Castrate-Resistant Prostate Cancer Patients Treated With Docetaxel
Contrast Media and Molecular Imaging
Medicine
Nuclear Medicine
Radiology
Imaging
Association Between New Unconfirmed Bone Lesions and Outcomes in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide
JAMA Oncology
Cancer Research
Oncology